PI3K pathway alterations were also frequent in invasive carcinomas NST (28 out of 88 cases, 31.8%), while such events were rare in ILC (1 out of 7 cases, 14.3%) and MED (1 out of 5 cases, 20%). This evidence concerns the gene PIK3CG and invasive carcinoma.